Nanopath Inc.

Nanopath Inc. is a woman-owned small business registered to receive federal government awards since December 2019. The company specializes in developing innovative diagnostic technologies for rapid pathogen detection and characterization, with a focus on point-of-care applications. Nanopath's core technology involves proprietary nanosensor-based systems that can identify pathogens and antibiotic resistance markers directly from patient samples within minutes, without the need for traditional culture or nucleic acid amplification methods. Their work primarily targets improving diagnostic workflows for common infections such as urinary tract infections (UTIs), aiming to expedite treatment and combat antibiotic resistance.

Through federal grant awards, Nanopath Inc. has received funding to advance its diagnostic platform for multiple applications. The National Institute of Allergy and Infectious Diseases (NIAID) awarded the company a $996,726 grant to develop a 15-minute point-of-care molecular diagnostic test for UTIs, capable of identifying pathogens and antibiotic resistance markers directly from urine samples. This project aims to expand the detection panel to cover over 95% of UTI-causing organisms and optimize the assay cartridge design. Additionally, the National Science Foundation (NSF) provided a $997,781 cooperative agreement under its Technology, Innovation, and Partnerships program for Nanopath to further develop its integrated point-of-care system for rapid pathogen identification and characterization. This NSF-funded project focuses on nanosensor fabrication, data analysis optimization, and system integration for single-step operation. Nanopath also received a smaller $255,874 NSF grant through the Engineering program to specifically target the development of a rapid pathogen identification system for UTIs. These grant-funded projects demonstrate Nanopath's commitment to advancing diagnostic technologies that can significantly improve patient care and antibiotic stewardship across various infectious disease scenarios.